Prognostic prediction models for pregnancy complications in women with gestational diabetes: a protocol for systematic review, critical appraisal and meta-analysis by Cooray, S.D. et al.
PROTOCOL Open Access
Prognostic prediction models for
pregnancy complications in women with
gestational diabetes: a protocol for
systematic review, critical appraisal and
meta-analysis
Shamil D. Cooray1,2, Jacqueline A. Boyle1,3, Georgia Soldatos1,2, Lihini A. Wijeyaratne1 and Helena J. Teede1,2*
Abstract
Background: Gestational diabetes (GDM) is increasingly common and has significant implications during
pregnancy and for the long-term health of the mother and offspring. However, it is a heterogeneous condition
with inter-related factors including ethnicity, body mass index and gestational weight gain significantly modifying
the absolute risk of complications at an individual level. Predicting the risk of pregnancy complications for an
individual woman with GDM presents a useful adjunct to therapeutic decision-making and patient education.
Diagnostic prediction models for GDM are prevalent. In contrast, prediction models for risk of complications in
those with GDM are relatively novel. This study will systematically review published prognostic prediction models
for pregnancy complications in women with GDM, describe their characteristics, compare performance and assess
methodological quality and applicability.
Methods: Studies will be identified by searching MEDLINE and Embase electronic databases. Title and abstract
screening, full-text review and data extraction will be completed independently by two reviewers. The included
studies will be systematically assessed for risk of bias and applicability using appropriate tools designed for
prediction modelling studies. Extracted data will be tabulated to facilitate qualitative comparison of published
prediction models. Quantitative data on predictive performance of these models will be synthesised with meta-
analyses if appropriate.
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Discussion: This review will identify and summarise all published prognostic prediction models for pregnancy
complications in women with GDM. We will compare model performance across different settings and populations
with meta-analysis if appropriate. This work will guide subsequent phases in the prognosis research framework:
further model development, external validation and model updating, and impact assessment. The ultimate model
will estimate the absolute risk of pregnancy complications for women with GDM and will be implemented into
routine care as an evidence-based GDM complication risk prediction model. It is anticipated to offer value to
women and their clinicians with individualised risk assessment and may assist decision-making. Ultimately, this
systematic review is an important step towards a personalised risk-stratified model-of-care for GDM to allow
preventative and therapeutic interventions for the maximal benefit to women and their offspring, whilst sparing
expense and harm for those at low risk.
Systematic review registration: PROSPERO registration number CRD42019115223
Keywords: Gestational diabetes, Prediction model, Prognosis, Pregnancy complications, Macrosomia, Systematic
review
Background
Gestational diabetes (GDM) is a state of carbohydrate in-
tolerance resulting in hyperglycaemia that commences or is
first recognised during pregnancy [1]. The prevalence of
GDM is rising in the context of increasing maternal age
and obesity, and introduction of new diagnostic criteria [2],
representing a public health concern internationally [1].
Recent data found the prevalence of GDM to be approxi-
mately 13% [3], while in high-risk populations including
some ethnic groups, prevalence is as high as 30% [4].
A diagnosis of GDM implies a state of glucometabolic
dysfunction which is associated with an increased risk of
pregnancy complications affecting the mother and fetus
as well as having significant implications for the long-
term health of the mother and offspring [5]. Landmark
randomised controlled trials have demonstrated reduc-
tion in pregnancy risks with GDM management consist-
ing of lifestyle modification and pharmacologic therapy,
albeit based on less inclusive diagnostic criteria [6, 7].
New consensus-based diagnostic criteria were devel-
oped by the International Association of Diabetes in
Pregnancy Study Groups (IADPSG) [8]. These criteria
that generally include lower glucose cut-off levels are
based on observational data [9] and remain highly con-
troversial. These were endorsed by the World Health
Organisation (WHO) and subsequently recommended
by some [10] but not all professional societies [11].
Other societies acknowledge that different diagnostic
criteria exist and that the optimal diagnostic strategies
may vary depending on the characteristics of the local
population [12–14].
Contemporary approaches to the diagnosis and manage-
ment of GDM, regardless of diagnostic criteria, are gluco-
centric [15, 16]. Risks related to glucometabolic dysfunction
are dichotomised on blood glucose levels into a binary yes/
no GDM state. A one-size-fits-all model of intervention is
then implemented, targeting glucose levels alone. This
approach fails to appreciate the continuum of risk associ-
ated with blood glucose levels and the increased clinical
heterogeneity of this condition, related primarily to ethni-
city [17], increasing obesity [18, 19] and increasing excess
gestational weight gain (GWG) [20]. These risk factors in-
dependently affect risk of diagnosis of GDM and short and
long-term health outcomes for affected women [17–20].
This heterogeneity is likely explained by emerging physio-
logic data suggesting highly variable degrees of beta-cell
function and insulin resistance amongst women diagnosed
with this condition [21].
Limitations of this glucocentric approach and lack of risk
stratification are evident from epidemiologic outcome data
following the adoption of the new IADPSG diagnostic cri-
teria. As expected, the application of these criteria have led
to an increase in GDM incidence, with maternity centres
reporting increases in the number of diagnoses by 28 to 74%
[22–25]. This increasing incidence is most likely due to a
change from a two- to one-step testing procedure and more
inclusive blood glucose level criteria rather than changes in
population characteristics. As such, a greater proportion of
pregnancies are identified as being at high risk and treated
with a package of care that includes additional education,
lifestyle modification and pharmacologic therapy. However,
intervening in a greater proportion of pregnancies has not
led to an overall reduction in pregnancy complications [22,
26, 27] yet has increased the overall costs of GDM care [22]
and psychosocial burden for affected women [28]. There-
fore, there is a mandate to develop a more sophisticated
prognosis and risk-stratified focused approach to GDM con-
sidering other relevant clinical factors driving adverse out-
comes in addition to glycaemic measures.
A suitable and effective prognostic prediction model will
allow calculation of the absolute risk of pregnancy compli-
cations for women with GDM who present for pregnancy-
care based on their unique individual characteristics includ-
ing BMI, GWG, ethnicity and obstetric history. Calculation
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of absolute risk of complications can then facilitate the de-
velopment of stratified models-of-care that better meet the
needs of women with this heterogeneous condition. This
personalised medicine approach will facilitate the transition
to a model-of-care where education, resources and
specialist-care can be directed to those women most likely
to benefit and sparing expense and unnecessary treatment
from those who will not.
This review will answer the question, what prognostic
prediction models have been developed for application to
pregnancies affected by GDM to predict pregnancy compli-
cations and inform clinical therapeutic decision-making?
The objectives of this systematic review are
1. To identify existing prognostic prediction models
for pregnancy complications in women with GDM;
2. To describe characteristics of the identified
prognostic prediction models qualitatively;
3. To compare the performance of identified
prognostic prediction models quantitatively across
different settings and populations with the use of
meta-analysis if appropriate;
4. To critically assess the conduct and reporting of
methods of these prediction studies.
Methods/design
This protocol is reported according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
Protocols (PRISMA-P) guideline [29] and the correspond-
ing checklist used (Additional file 2). This systematic review
protocol was registered on the PROSPERO international
registry of systematic reviews on January 18, 2019
(CRD42019115223).
A systematic review of prediction modelling studies for
pregnancy complications in women with GDM will be con-
ducted to identify eligible studies published before Decem-
ber 2018. This review forms the foundations of a broader
research program guided by the recommendations of The
PROGnosis RESearch Strategy (PROGRESS) Partnership,
an international, interdisciplinary collaboration that has
published a framework to improve the standards of progno-
sis research to improve its translational impact. The fram-
ing of the review question (Table 1), study design, data
extraction and appraisal will be guided by recent develop-
ments in prognosis research methodology, which seek to
improve rigour and reproducibility. This includes the
Cochrane Prognosis Methods Group Protocol Template
[33], the TRIPOD statement (transparent reporting of a
multivariable prediction model for individual prognosis or
diagnosis) [34], the CHARMS checklist (checklist for crit-
ical Appraisal and data extraction for systematic reviews of
prediction modelling studies) [30] and the PROBAST tool
(prediction model risk of bias assessment) [35].
Eligibility criteria
Study selection will be based on pre-determined eligibil-
ity criteria framed using the PICOTS system [36]
(Table 2). PICOTS is a modification of the established
PICO system tailored to the specific requirements of sys-
tematic reviews of prediction models with additional
consideration for timing (both for the time period of the
prediction and the time point at which the prediction
model is to be used) and clinical setting [35].
Population
Studies reporting on prediction models proposed for preg-
nant women with GDM will be considered for inclusion.
GDM may have been diagnosed by any criteria. Studies
proposing models for pregnant women with pre-gestational
diabetes (type 1 and type 2 diabetes) will be excluded.
Intervention
Prediction model development studies with and without
external validation and external model validation studies
with or without model updating will be considered for
inclusion if they are intended to inform clinicians’ thera-
peutic decision making regarding the management of a
pregnancy affected by GDM.
Outcomes
The included pregnancy complications related to GDM
and their prioritisation were aligned with those agreed by
consensus of the Cochrane Pregnancy and Childbirth
Group responsible for systematic reviews for prevention
and treatment of GDM and pre-existing diabetes [31, 32]
and drew on published search strategies for similar review
questions [20, 38]. The timing and effect measures for
each outcome will be as defined by the study’s authors.
Complications potentially related to the treatment of
GDM such as maternal hypoglycaemia and glycaemic
control were not included. GWG was not included as it is
also likely to be a predictor of the outcomes of interest.
Timing
Included studies need to report on prediction models for
complications occurring during pregnancy or the postpar-
tum period or affecting the neonate. The standard defin-
ition of neonate will be used, that is, an infant during the
first 28 days after birth. Prediction models for complications
with onset after this period will be excluded.
Setting
Prediction models that are intended to be used by health-
care professionals in the antenatal clinic setting, at any
time during pregnancy will be considered for inclusion.
Models intended to be used before (pre-conception) or
after (post-partum) will be excluded.
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Types of studies and limits
Any study design including primary research (e.g. rando-
mised controlled trial or observational study) that reports
on one or more statistical models, tools or scores with at
least two predictors proposed to predict an individual’s risk
of a future outcome (prediction modelling studies) will be
considered for inclusion. Other names for prediction
models include prognostic model, prognostic (or predic-
tion) index or rule, risk (or clinical) prediction model and
predictive model. Risk predictions are usually expressed in
absolute terms as a probability, i.e. 0 to 100% (but can be
relative (risk score) [39]. Any identified and relevant review
articles will be used to identify eligible primary studies.
Studies will be limited to those conducted in humans
by applying The Cochrane Group’s filter for Humans
not Animals filter [40]. There will be no limits on the
year of publication hence included articles will be from
all years in the MEDLINE (from 1946) and Embase
(from 1947) databases. No restriction to language of
publication will be applied.
Search methods for identification of studies
Information sources
The following electronic databases will be searched to
identify eligible studies:
Table 1 Framing of this systematic review using key items identified by the CHARMS checklist [30]
Item Comments
1. Prognostic versus diagnostic prediction model Aim is to predict future events (prognostic prediction model)
2. Intended scope of the review Models to inform clinicians’ therapeutic decision-making
3. Type of prediction modelling studies All study types, i.e. Prediction model development studies with and without
external validation and external model validation studies with or without
model updating.
4. Target population to whom the prediction model applies Pregnant women with gestational diabetes diagnosed according to each
included study.
5. Outcome to be predicted Pregnancy complications related to GDM affecting the mother (obstetric or
maternal) or the child (fetal or neonatal). These complications were aligned
with the standard outcomes agreed by consensus between review authors
of Cochrane Pregnancy and Childbirth systematic reviews for the prevention
and treatment of GDM and pre-existing diabetes [31, 32]. Complications
potentially related to the treatment of GDM such as maternal hypoglycaemia
and glycaemic control were not included. Gestational weight gain was not
included as it is also likely to be a predictor of the outcomes of interest.
Mother:











• Large-for-gestational age neonate
• Nirth trauma including shoulder dystocia, nerve palsy, bone fracture
• Fetal macrosomia
• Small-for-gestational age neonate
• Low birth weight neonate
• Intrauterine growth restriction
• Preterm birth
• Neonatal hypoglycaemia





• Apgar sore < 7 at 5 min
• Admission to neonatal intensive care unit or special care nursery
6. Time span of prediction Complications occurring during pregnancy (obstetric) or affecting the neonate
(neonatal), defined per standard definition which is an infant during the first
28 days after birth.
7. Intended moment of using the model At any time during pregnancy.
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Table 2 Eligibility criteria for the systematic review framed using the PICOTS system [36]
Inclusion criteria Exclusion criteria
Population Women with gestational diabetes
(any diagnostic criteria).
Women with pre-gestational diabetes
(type 1 and type 2 diabetes).
Index Development or external validation
of a prognostic prediction model for
women (e.g. prediction model for
women with gestational diabetes to
predict pregnancy complications)
Diagnostic prediction models (e.g.
prediction model for the diagnosis of GDM)
Comparator Not applicable
Outcomes (primary) Obstetric:
- Hypertensive disorders of pregnancy
- Caesarean delivery
Neonatal:
- Large-for-gestational age (LGA)
- Composite of perinatal (fetal and neonatal)
mortality or serious morbidity* (e.g. birth











- Perinatal (fetal and neonatal) mortality
- Serious morbidity (e.g. birth trauma,
shoulder dystocia, bone fracture or nerve palsy)
- Fetal macrosomia
- Small-for-gestational age (SGA)
- Low birth weight
- Intrauterine growth restriction (IUGR)
- Preterm delivery or premature birth
- Neonatal hypoglycaemia





- Apgar score < 7 at 5 min
- Admission to neonatal intensive care unit
Timing Complications occurring during pregnancy
or up to 6 weeks postpartum period
(obstetric or maternal) or affecting the
neonate (neonatal).
Complications affecting the mother
pre-pregnancy or with an onset more
than 6 weeks postpartum. Complications
affecting the offspring after 28 days of age.
Setting Prognostic prediction models that are
intended to be used by healthcare
professionals, in the antenatal clinic
setting, at any time during
pregnancy intended to inform clinicians’
therapeutic decision-making.
Prognostic prediction models, which are
intended to be used before pregnancy
(pre-conception) or after childbirth.
Study type Any study design including primary research
(e.g. randomised controlled trial, cohort study,
case-control study) or secondary research
(e.g. systematic review) that reports on
(ii) one or more statistical models, tools or
scores with at least two predictors proposed
to predict an individual’s risk of a future outcome
(prediction modelling studies). Other names for
prediction models include prognostic model,
prognostic (or prediction) index or rule, risk
(or clinical) prediction model and predictive model.
Prediction models estimate the risk of experiencing
Editorial comments or letters.
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 Ovid MEDLINE(R) and Epub Ahead of Print, In-
Process and Other Non-Indexed Citations, Daily and
Versions(R) on OvidSP (from 1946 to present)
 Embase Classic+Embase on OvidSP (from 1947 to
present)
The reference list of included studies will be hand
searched for additional potentially relevant citations.
Search strategy
A sensitive search strategy, based on the eligibility cri-
teria and combining subject indexing terms (i.e. MeSH)
and free-text search terms in the title and abstract fields,
will be developed for MEDLINE using the OvidSP plat-
form. The search strategy, specifically, subject indexing
terms will be translated appropriately for Embase.
The search strategy will be iteratively developed and re-
fined with the assistance of clinical advisors (HJT, JAB and
GS), a medical librarian and an evidence synthesis expert.
The final search strategy will combine concepts related to
prognostic factors and prediction modelling studies, GDM
and pregnancy complications. The updated version of a
validated filter for prediction modelling studies published
by Geersing and colleagues [41] (based on the original
published by Ingui and colleagues [42]) will be used. For
GDM, a search strategy published in a peer-reviewed sys-
tematic review of treatments for this condition will be
used [43]. These two concepts will be combined with a be-
spoke search strategy for pregnancy complications related
to GDM defined as the outcomes of interest in the eligibil-
ity criteria (Table 2). The draft search strategy is provided
in Additional file 1: Table S1.
A backward citation search will be conducted on all
model development studies. All retrieved studies will be
reviewed to identify all relevant external validation
studies.
Data collection and analysis
Data management
Retrieved studies will be imported into Endnote refer-
ence manager software. (Version X8.2, Clarivate Analyt-
ics, Philadelphia, USA. Available at https://endnote.com/
) Duplicate records will be identified and excluded using
a systematic, rigorous and reproducible method utilising
a sequential combination of fields including author, year,
title, journal and pages [44]. Covidence systematic
review software will be used to manage records through-
out the review. (Veritas Health Innovation, Melbourne,
Australia. Available at http://www.covidence.org).
Selection process
Two reviewers (SDC, LAW) will independently screen
the titles and abstracts of every article retrieved by the
search strategy according to the selection criteria
(Table 2). Full text of the articles will be retrieved for
further assessment if the information given suggests that
the study meets the selection criteria or if there is any
doubt regarding eligibility of the article based on the in-
formation given in the title and abstract. Any disagree-
ment will be resolved by discussion to reach a consensus
and consultation with an advisor (HJT) if required. For
publications in languages other than English portions of
the title, abstract and full-text article will be translated
as necessary. A record of all retrieved studies will be
maintained and reasons for exclusion documented.
Data extraction
Two reviewers (SDC, LAW) will independently extract
the data from the included studies using a standardised
electronic form developed with reference to the CHeck-
list for critical Appraisal and data extraction for system-
atic Reviews of prediction Modelling Studies (CHARMS)
[30]. Variables for which data will be sought will include
information on objective, source of data, participants,
outcome(s) to be predicted, candidate predictors, sample
size, missing data, model development, model perform-
ance (discrimination, calibration and measures of case-
mix variation), results including final multivariable
models and interpretation of presented models [30].
Data on diagnostic approach for GDM used (diagnostic
criteria, testing procedures and screening policies),
whether population was treated and treatment type will
also be extracted. Any disagreement will be resolved by
discussion to reach a consensus and consultation with
an advisor (HJT) if required. Missing data will be ob-
tained from the authors wherever possible; if insufficient
information is obtained the study will be excluded.
Critical appraisal
The methodological quality (risk of bias) and relevance
(applicability) to the review question of included studies
will be systematically assessed using the prediction
Table 2 Eligibility criteria for the systematic review framed using the PICOTS system [36] (Continued)
Inclusion criteria Exclusion criteria
the outcome and may be reported in absolute
(absolute probability) or relative (risk score)
terms [37]. Prediction modelling studies can be
either model development, model validation or a
combination.
*For studies set in low and middle-income countries perinatal mortality and serious morbidity will be assessed as individual primary outcomes
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model risk of bias assessment tool (PROBAST) [35].
This tool is structured around four key domains: partici-
pants, predictors, outcome and analysis. Each domain is
rated as “high”, “low” or “unclear” risk of bias. Two re-
viewers (SDC, LAW) will independently evaluate the risk
of bias and applicability of each included study. Any dis-
agreement will be resolved by discussion to reach a con-
sensus and consultation with an advisor (HJT) if
required. Results will be presented graphically with each
study given a rating of low, unclear or high risk for each
of the four domains.
Qualitative data synthesis of prediction models
All extracted data on prediction models from included
studies will be tabulated to facilitate comparison of out-
comes to be predicted, predictors included in the final
model and performance measures [30, 38]. Measures of
uncertainty will be reported when published or approxi-
mated using published methods [36]. Where reported,
classification measures such as sensitivity, specificity,
positive predictive value and negative predictive value
will also be included [30, 38]. A descriptive analysis of
key items will also be presented.
Quantitative analysis and comparison of the predictive
performance of prediction models
The nature of the quantitative analysis will be dependent
on the number of prediction models identified in the
systematic review and the type of prediction modelling
study (i.e. development or validation).
Data will be synthesised by performing meta-analysis by
type of prediction modelling study if feasible and identified
prediction models are sufficiently homogenous. Clinical
homogeneity will be satisfied if the review identifies:
a) Multiple validation studies for a common prediction
model are identified or
b) Multiple development studies where the target
population to whom the model applies, outcome to
be predicted and intended moment of using the
model are considered similar.
Meta-analysis and investigation of heterogeneity
Where meta-analysis is feasible, performance measures
such as discrimination (e.g. concordance (c) statistic or
area under the curve) and calibration (e.g. total number of
observed to expected events ratio [total O:E ratio]] and
calibration slope) will be will be pooled and analysed using
a random-effects meta-analysis model to provide estimates
of the average performance of the model across the in-
cluded studies. To estimate the between-study heterogen-
eity and the 95% confidence intervals for this average
performance, the restricted maximum likelihood and the
Hartung-Knapp-Sidik-Jonkman methods will be used
respectively [36]. Meta-analysis will be conducted with ref-
erence to the Meta-analysis of Observational Studies in
Epidemiology (MOOSE) group guidelines [45] using the
metareg module in Stata (StataCorp).
Heterogeneity in performance measures is anticipated
and will likely reflect the heterogeneity of study design
and population [36]. The range of potential model per-
formance in a different population in a new validation
study will be estimated by calculating an approximate
95% prediction interval [36]. Case-mix variation within
each study will be quantified by estimating the standard
deviation of the linear predictor [36]. When performance
measures or measures of uncertainty have not been re-
ported, they will be approximated where possible using
appropriate methods [36]. Statistical homogeneity will
be assessed using the I2 test where I2 values over 50% in-
dicate moderate to high heterogeneity [46]. Potential
sources of heterogeneity will be investigated by under-
taking a meta-regression analysis.
Analysis of subgroups
Where there are sufficient number of included studies
sub-group analyses will be undertaken.
Subgroup analyses will be conducted according to the
type of prediction modelling study (development and/or
validation), target population to whom the prediction
model applies as defined by diagnostic approach to
GDM (diagnostic criteria, testing procedures and screen-
ing policies), testing procedures or screening policies for
GDM used, whether population was treated (yes/no),
treatment type, outcome to be predicted, intended mo-
ment of using the model and study quality (risk of bias).
Sensitivity analysis
Sensitivity analyses will be performed for studies at
lower and higher risk of bias to explore the influence of
risk of bias on effect size [36].
Reporting and presentation of findings
Reporting and presentation of results will be guided by
the PRISMA statement (preferred reporting items for sys-
tematic reviews and meta-analyses) [47]. Relevant recom-
mendations from the TRIPOD statement (transparent
reporting of a multivariable prediction model for individ-
ual prognosis or diagnosis) [34] will also be considered.
The GRADE approach (grading of recommendations,
assessment, development and evaluation) will be applied
to determine confidence in estimates [48, 49].
Discussion
This systematic review will identify all published prog-
nostic prediction models for pregnancy complications in
women with GDM. These prognostic prediction models
will be comprehensively summarised and their
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performance compared across different settings and
populations with meta-analysis if appropriate.
A prognostic prediction model for GDM that is
intended to aid therapeutic decision-making during preg-
nancy would ideally integrate clinically meaningful and
patient aligned outcomes including pregnancy complica-
tions affecting mother and baby. Long-term outcomes af-
fecting maternal health such as progression to type 2
diabetes and resultant increased cardiovascular risk for
mother and affecting offspring health such as increased
risk of childhood obesity for offspring are important.
However, they are less likely to have a significant bearing
on clinical decision-making during the pregnancy itself.
Rather prediction of long-term risks should facilitate the
targeting of preventative interventions post-partum.
Prognosis-related research in GDM is a relatively novel
field of enquiry. The glucometabolic health and out-
comes of a pregnant woman are influenced by a number
of clinical factors, including glucose levels, body mass
index (BMI), GWG and ethnicity [17–20]. These predic-
tors have been incorporated into prediction models but
to date, the focus has been on GDM diagnosis rather
than prognosis after GDM diagnosis. Diagnostic predic-
tion models seek to predict the risk of GDM diagnosis
based on routinely available clinical parameters with a
view to directing screening and/or primary prevention
efforts. Multiple diagnostic prediction models have been
developed [38], including our own [50], and 12 were re-
cently externally validated and compared head-to-head
in a prospective cohort [51].
The utility of diagnostic prediction models for GDM diag-
nosis is limited in contemporary clinical practice because
case-finding based on high-predicted risk of diagnosis has
been superseded by universal screening at 24–28weeks ges-
tation in most guidelines. Furthermore, guidelines are in-
creasingly recommending first-trimester screening for type 2
diabetes in women at high risk, identified by the presence of
one or more risk factors [10, 12, 13]. Although widely as-
sumed in routine clinical practice the benefit of early diag-
nosis and treatment is yet to be demonstrated and thus is
currently subject to a randomised controlled trial [52].
This review will make an important contribution to
the understanding of the risk of pregnancy complica-
tions for women with GDM. Furthermore, it will pro-
mote the consideration of the broad continuum of risk
related to this condition in routine clinical practice. If
this review does not identify any applicable models or
applicable models have poor performance and or
methodological quality, then these results will provide
rationale and guidance for model development and/or
updating. Conversely, if this review identifies a prog-
nostic model with high predictive performance, applic-
ability and methodological quality, then such a model
could be implemented and would be valuable to
clinicians caring for women with GDM. It would allow
clinicians to predict an individual’s absolute risk of
pregnancy complications. This prediction could also
help affected women understand the implications of
GDM on their pregnancy and in doing so, promote
shared decision-making with clinicians that consider
individual risk estimated objectively and systematic-
ally. At a health service level, the implementation of
such prediction models would support a personalised
risk-stratified model-of-care, which would ultimately
better direct finite health resources to women at high-
risk and most likely to benefit from intervention.
As such, this systematic review serves as the foundation
for a body of work to develop, validate, implement and
evaluate the impact of a prognostic prediction model for
pregnancy complications related to GDM across the four
themes of the PROGRESS prognosis research framework
[53]. Theoretical prediction models not implemented into
clinical practice are a waste of research effort and re-
sources. Hence, the authors’ will adopt a model aggrega-
tion approach to develop a meta-model which optimally
captures prior knowledge by combining model validation
and updating of the existing prediction models identified
in this review [54]. The performance of the meta-model
will be compared to existing single models identified in
this review, facilitating the selection of the prognostic pre-
diction model most suitable for application into clinical
practice. This model will become the subject of imple-
mentation research. An impact study will be designed and
conducted to compare a model-of-care based on the dir-
ective use of the prediction model to stratify women to
targeted interventions based on their risk of pregnancy
complications compared to usual care [55]. Such a study
would also facilitate evaluation of the implementation of
this prognostic model into the model-of-care including its
acceptability to clinicians and impact on health service
utilisation and costs.
Ultimately, this systematic review is an important step
towards developing and implementing personalised risk-
stratified models-of-care for GDM. This will allow pre-
ventative and therapeutic interventions to be precisely
targetted at women most likely to benefit, and sparing
expense and harm for those who will not.
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